Gilead Sciences
As of the edition of 20 October 2026, Gilead Sciences runs 136 drugs, 30 of them marketed; it is on route A at 27 targets and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Gilead Sciences was renamed in 2024.
The records place 7 company names in this family.
- CV Therapeutics, Inc.: renamed in 2024
- Arcellx, Inc.: acquired in 2026; successor CV Therapeutics, Inc.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 30 |
| Active | 33 |
| Went quiet | 24 |
| Stopped | 41 |
| Status not established | 8 |
| Total | 136 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tenofovir disoproxil | none listed | 0 |
| Emtricitabine | Ends 2032 (patent) | 0 |
| Sofosbuvir | Ends 2034 (patent) | 0 |
| Tenofovir alafenamide | Ends 2032 (patent) | 0 |
| Sacituzumab govitecan | Ends 2032 (computed from the first US licence) | 2 |
| Cobicistat | Ends 2032 (patent) | 0 |
| Ledipasvir | Ends 2034 (patent) | 0 |
| Velpatasvir | none listed | 0 |
| Rilpivirine | Ends 2027 (exclusivity) | 0 |
| Remdesivir | Ends 2035 (patent) | 0 |
| Ranolazine | none listed | 4 |
| Filgotinib | none listed | 3 |
| Idelalisib | Ends 2033 (patent) | 1 |
| Adefovir dipivoxil | none listed | 0 |
| Ambrisentan | none listed | 2 |
| Regadenoson anhydrous | Ends 2027 (patent) | 2 |
| Axicabtagene ciloleucel | Ends 2033 (orphan exclusivity) | 0 |
| Bictegravir | Ends 2035 (patent) | 0 |
| Aztreonam | none listed | 0 |
| Elvitegravir | Ends 2026 (patent) | 0 |
| Lenacapavir | Ends 2038 (patent) | 0 |
| Cidofovir anhydrous | none listed | 0 |
| Voxilaprevir | none listed | 0 |
| Bulevirtide | Ends 2038 (computed from the first US licence) | 1 |
| Brexucabtagene autoleucel | Ends 2032 (computed from the first US licence) | 0 |
A route B row is one company at one target. 5 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 27 targets, route B at 8 targets.
All 35 rows on route A or B
In the product35 company-target rows on route A or B; 32 are not shown here, and no score is.
See all 35 targets where Gilead Sciences needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 205 trials led
- Digestive system: 199 trials led
- Immune system: 151 trials led